Congress doubles pharma tax break for rare-disease drugs—no price controls attached
H.R. 1414 — Cameron’s Law · Filed by Josh Gottheimer (D-NJ) · 19 cosponsors · Introduced Feb 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill doubles the orphan drug tax credit from 25% to 50% for pharmaceutical companies developing drugs for rare diseases. The credit applies to qualified clinical testing expenses, allowing companies to deduct a larger percentage of their R&D costs against federal taxes, effective immediately upon enactment.
Why we flagged it
The bill's operative mechanism is a direct reduction in federal tax liability for pharmaceutical companies engaged in orphan drug development. It is a tax expenditure — a subsidy delivered through the tax code rather than direct appropriation — and benefits a specific industry sector.
What the text implies
- The bill does not condition the tax credit on drug affordability, price caps, or patient access — companies may claim the full credit while charging high prices for resulting treatments.
- Doubling the credit increases federal revenue loss (a cost to the general taxpayer) with no sunset or review mechanism; the benefit is permanent unless Congress acts again.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies developing orphan drugs; biotech firms with rare-disease pipelines